Understanding The Mechanisms Of Functionally Selective Antipsychotic Drugs: Implications For New Generation Antipsychotic Drugs
Funder
National Health and Medical Research Council
Funding Amount
$371,745.00
Summary
Schizophrenia is a chronic and devastating disease that ranks among the top 10 disabilities in developed countries. It places a significant burden on the Australian health system, costing about $1.5 billion each year. This project aims to reveal the mechanisms of new functionally selective antipsychotic drugs, which achieve an excellent therapeutic efficacy with low side-effects. Understanding these mechanisms will provide novel directions for the design of new generation antipsychotic drugs.
Cyclotherapy: A New Approach To Stop The Side Effects Of Chemotherapy
Funder
National Health and Medical Research Council
Funding Amount
$565,847.00
Summary
Cyto-toxic chemotherapy is a widely used treatment for cancer but is associated with significant side effects for the patient. These are due to the chemotherapy killing normal dividing cells in the gut, bone marrow and hair follicles. We will determine the potential of cyclotherapy in preventing these side effects. In cyclotherapy a pre-treatment temporarily stops normal cells from dividing and therefore protects them from the damage of subsequent chemotherapy.
Understanding The Mechanisms For Ameliorating/preventing Antipsychotic-induced Obesity In Early Life
Funder
National Health and Medical Research Council
Funding Amount
$576,496.00
Summary
There has been a sharp worldwide increase during the last decade in antipsychotic prescriptions (mostly “off-label”) to paediatric patients. One important issue is that antipsychotic drugs were developed for adult patients and normally have serious side-effects. This project will not only reveal the mechanisms of antipsychotic-induced obesity side-effects in youth, but will also explore intervention strategies for preventing antipsychotic-induced weight gain/obesity in paediatric patients.
Roles Of Muscarinic M3 Receptors In Antipsychotic-induced Metabolic Side-effects: Prevention And Treatment Of Antipsychotic-induced Insulin Dysregulation
Funder
National Health and Medical Research Council
Funding Amount
$603,825.00
Summary
Antipsychotic drugs are used to treat various mental disorders, such as schizophrenia, bipolar disorder, dementia and major depression. However, these drugs cause serious metabolic side-effects leading to premature death and huge costs to the Australian health care system. This project aims to reveal the role of muscarinic M3 receptors in antipsychotic-induced insulin dysregulation that precedes diabetes. Understanding these mechanisms will provide new strategies for the prevention and treatment ....Antipsychotic drugs are used to treat various mental disorders, such as schizophrenia, bipolar disorder, dementia and major depression. However, these drugs cause serious metabolic side-effects leading to premature death and huge costs to the Australian health care system. This project aims to reveal the role of muscarinic M3 receptors in antipsychotic-induced insulin dysregulation that precedes diabetes. Understanding these mechanisms will provide new strategies for the prevention and treatment of these critical adverse effects.Read moreRead less
TIR Signalling Pathway Pharmacogenomics And Opioid Response: Beyond The Mu Opioid Receptor
Funder
National Health and Medical Research Council
Funding Amount
$246,396.00
Summary
This project will identify why some people respond poorly and others have toxic side effects to the major group of pain relieving medications, the opioids. The basis will be the genetics of the immune system and both acute postoperative and chronic cancer pain patients will be studied in this international pharmacogenetics project.
Improving Risk Evaluation And Outcomes In Paediatric Acute Lymphoblastic Leukaemia
Funder
National Health and Medical Research Council
Funding Amount
$798,022.00
Summary
The main objective of this project is to make substantial improvements in the treatment of patients with childhood leukaemia by greater use of molecular diagnostics to measure minimal residual disease (MRD) and high risk genetic changes in Australian patients enrolled on an international clinical trial which has been designed to reduce the incidence of both relapses and long term side-effects.
Type I Interferon Signalling In Bacterial Infection
Funder
National Health and Medical Research Council
Funding Amount
$738,274.00
Summary
Infectious diseases are a leading cause of death in Australia. Activation of disease-fighting inflammasomes sets in motion rapid immune defenses against pathogens. In this project, we explore how cell-cell communication molecules known as type I interferons communicate with inflammasomes to achieve the best outcome in the body in response to deadly bacterial infection. Understanding how these signals communicate with one another could reveal new ways to fight infectious diseases.
Understanding Neuroinflammation In Alzheimer's Disease
Funder
National Health and Medical Research Council
Funding Amount
$1,043,216.00
Summary
This project opens a new line of enquiry into the cellular signalling mechanisms involved in the progression of AD and establishes whether targeting the involvement of type-1 IFN signalling influences the evolution of AD. New and novel approaches are clearly required to treat AD. Importantly, we believe that neuroinflammation is common to all causes of dementia and targeting the neuroinflammatory pathways has much wider implications than targeting the primary causative pathway.
Defining The Role Of RNA Editing In Erythropoiesis
Funder
National Health and Medical Research Council
Funding Amount
$628,945.00
Summary
We are seeking to understand how red blood cells are produced. We have identified that a process called RNA editing may be important in the regulating the production of red blood cells.
The Role Of Apoptotic Caspases In Regulating Type I Interferon Production
Funder
National Health and Medical Research Council
Funding Amount
$791,746.00
Summary
Type I interferons (IFNs) are potent anti-viral cytokines. Dysregulated type I IFN responses result in major pathologies, e.g., embryonic lethality and defects in tissue homeostasis. We have identified a novel molecular mechanism regulating IFN production that relies on the host’s own apoptotic caspases. We hypothesize that apoptotic caspases critically regulate IFN responses during the process of cell death, with implications for tissue homeostasis and host responses to infection.